Inhibition of hepatitis B virus in mice by RNA interference

By Anton P. McCaffrey, H. Nakai, K. Pandey, Zan Huang, F. Salazar, Hui Xu, S. Wieland, P. Marion, M. Kay. Nature Biotechnology, 2003

626 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Unlocking the potential of the human genome with RNA interference (2004, background): “The first demonstration of RNAi efficacy against a virus in vivo involved hydrodynamic co-delivery of an HBV replicon and an expression unit encoding an anti-HBV shRNA in mic”
RNAi therapeutics: principles, prospects and challenges. (2007, background): “The first demonstration of RNAi efficacy in vivo involved hydrodynamic co-delivery of a hepatitis B replicon and a pol III expression unit encoding an anti-hepatitis B virus (HBV) shRNA in mice [79].”
Current prospects for RNA interference-based therapies (2011, background): “RNAi-based therapies are also under development for hepatitis B virus (HBV”
Inhibition of respiratory viruses by nasally administered siRNA (2005, background): “In pioneering recent work, siRNA offered protection from hepatitis virus, and siRNA against the Fas antigen prevented liver damage resulting from fulminant hepatiti”
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors (2005, methodology): “The hydrodynamic injection method used in the first studies of in vivo protection from disease by siRNA”